Mobio Interactive addresses the global mental health crisis with unique IP and a proven, de-risked business model.
Problem
It is exceptionally difficult to deliver precision psychiatry at scale.
Solution
MI combines computer vision, AI and clinically validated psychotherapy, in a single, easy-to-use mobile platform.
Product: AmDTx, precision psychiatry at scale
Personalisation of mental healthcare via real time measurement of therapy efficacy with a validated digital biomarker of stress.
This solution is 100% MI IP, scales and integrates seamlessly into clinicians’ pre-existing workflows.
Business Model
Platform licensing to hospitals and payors establishes the critical infrastructure and ease of use that supports rapid prescription and adoption of regulated Class II SaMD interventions.
Competitive Advantages
- World’s most accurate objective quantification of stress from mobile selfie video (>80% accuracy*)
- >2.5 million digital biomarkers data points from >25k individuals from 175 countries.
- Clinically validated therapy
*Al-Jebrni et al., AI-enabled remote and objective quantification of stress at scale. BSPC 2020
Traction
- Established clients across three target verticals: Health Systems, Payors, Pharma
- FDA Breakthrough Device Designation pending
- Respected institutional investors
Opportunity & Impact
MI is rapidly approaching its next inflection point: FDA clearance. When this comes to pass, valuation will increase and new capital will be raised. Pre A investors guarantee FDA clearance.
Globally, more than 1 in 10 people need mental health therapy. Digital therapies for mental illness will reach $500 billion/yr by 2035. As an early leader, MI aims to capture 10% of this market opportunity as the first in history to achieve precision psychiatry at scale.
